Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 31, 2015 4:24 PM ET

Healthcare Providers and Services

Company Overview of Genzyme Polyclonals S.A.S.

Company Overview

Genzyme Polyclonals S.A.S. operates as a subsidiary of Genzyme Corporation.

Les Carrés du Parc

10 rue des Rosiéristes - BP 54

Champagne au Mont D´Or

Rhone,  69543

France

Phone:

33 4 37 28 16 00

Fax:

33 4 37 28 16 79

Key Executives for Genzyme Polyclonals S.A.S.

Chief Executive Officer and Chief Operating Officer
Age: 60
Compensation as of Fiscal Year 2015.

Genzyme Polyclonals S.A.S. Key Developments

Sanofi and Genzyme Announces New Magnetic Resonance Imaging Data from the Lemtrada Clinical Development Program

Sanofi and its subsidiary Genzyme announced that new magnetic resonance imaging data from the Lemtrada clinical development program will be presented at the 67th American Academy of Neurology Annual Meeting. In relapsing remitting multiple sclerosis patients treated with Lemtrada in the Phase III pivotal studies, MRI effects observed in the two-year trials were maintained through two additional years in the extension study. After the initial two courses of treatment in the pivotal studies, which were given at month zero and at month 12, approximately 70% of Lemtrada patients did not receive additional Lemtrada treatment during the following three years, through month 48. The Phase III trials of Lemtrada were randomized, two-year pivotal studies comparing treatment with Lemtrada to high-dose subcutaneous interferon beta-1a in patients with RRMS who had active disease and were either new to treatment or who had an inadequate response to another therapy. Through year four, the adverse event profile of Lemtrada was consistent with that observed during the pivotal studies. The new data being presented at AAN include: The rate of brain atrophy, as measured by brain parenchymal fraction, decreased progressively over four years among Lemtrada patients in CARE-MS I. Among CARE-MS II Lemtrada patients, the rate of brain atrophy decreased progressively over three years and remained low in year four. In both studies, the median yearly brain volume loss was less than -0.20% in years three and four, which was lower than what was observed during the two-year pivotal studies. In CARE-MS I and II, treatment with Lemtrada significantly reduced the risk of developing new lesions compared to interferon beta-1a. In the extension study, most of the Lemtrada-treated patients from CARE-MS I and II were free of new lesions and MRI activity in years three and four. Brain atrophy is a measure of the most destructive pathological processes that occur in MS. 1 It is seen from the earliest stages of disease and may lead to irreversible neurological and cognitive impairment. Given its association with disability, control or prevention of brain atrophy is an important target for MS treatment. In addition, MRI measures including lesion activity are considered useful tools when evaluating the effect of MS therapies, and lesion activity is among several prognostic factors for unfavorable clinical outcomes.

Cystic Fibrosis Foundation Therapeutics Announces $14 Million Research Expansion with Genzyme

Cystic Fibrosis Foundation Therapeutics Inc. has announced a $14 million expansion of its research agreement with Genzyme to promote development of new treatments for people with the most common CF mutation, F508del. The agreement will support research and development programs aimed at identifying compounds, known as correctors, that could potentially fix the defective CFTR protein in people with CF. The F508del mutation causes a folding problem in the defective protein that disrupts its movement to the surface of the cell, where it is needed to regulate the flow of salt and fluids in and out of the cell. Nearly 90% of people with CF have at least one copy of the F508del mutation. During the expansion phase, Genzyme will focus on further developing select compounds to advance them into CF clinical trials.

Genzyme Presents at BIO-Europe Spring 2015, Mar-09-2015 09:00 AM

Genzyme Presents at BIO-Europe Spring 2015, Mar-09-2015 09:00 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France. Speakers: Robin Kenselaar, VP, Europe, Middle East, Africa.

Similar Private Companies By Industry

Company Name Region
SAM Service Assistance Maison Europe
PasteurMed Europe
Ouest Répartition SA Europe
AplusA Europe
Institut Alfred Fournier Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genzyme Polyclonals S.A.S., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.